Oxford, UK, 16 November 2021: SpyBiotech, a biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointment of Simon Jones as VP of Finance and Operations, and the expansion of its scientific team with four new hires. Simon takes up the permanent position of VP Finance […]
A study from Scripps using SpyTag/SpyCatcher technology shows that the receptor-binding domain and stabilized SARS-CoV-2 spike displayed on ferritin nanoparticles as vaccine antigens, elicited potent immune responses. Click link here for the paper (14 Sept, 2020)
New technology platform helps accelerate vaccine generation SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments. “The COVID-19 vaccine uses SpyBiotech’s unique protein “superglue”
SpyBiotech featured in The Guardian Value of Vaccines supplement Read More »
Oxford, U.K., March 8, 2021: SpyBiotech, a British biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointments of Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor. Mr Menichella brings with him over 20 years of executive and leadership experience
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development SpyBiotech has raised $32.5M from leading investors to advance development of its novel “plug and display” vaccine platform technology Braavos Investment Advisers led the round, joined by new investor Oxford Investment
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman Read More »
Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first subjects in a Phase I/II trial of a novel virus-like particle (VLP) vaccine targeting COVID-19. SpyBiotech has signed an exclusive
2 recent papers with really interesting results! Click here to read the full paper on computationally designed VLPs. Results: RBD can be efficiently displayed on the mi3 VLP via SpyTag/SpyCatcher RBD-SpyVLP is reactive to monoclonal antibodies isolated from recovered patients RBD-SpyVLP induces a strong ACE2-blocking and neutralising antibody response in mouse models RBD-SpyVLP is highly
